The 2 Wall Street analysts covering Inogen, Inc. hold a median 12-month price target of $12 — +102.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 8 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Inogen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (88): The business earns solid, repeatable profits on what it owns.
Momentum (32): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INGN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +102.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Apr 2026 | Freedom Broker | Initiates | Buy | $12 |
| 16 June 2025 | B. Riley Securities | Initiates | Buy | — |
| 22 May 2025 | Needham | Upgrade | Buy | — |
| 8 May 2025 | Stifel | Maintains | Hold | — |
| 9 Apr 2025 | Needham | Reiterates | Hold | — |
| 27 Feb 2025 | Needham | Reiterates | Hold | — |
| 26 Feb 2025 | Needham | Reiterates | Hold | — |
| 30 Jan 2025 | Needham | Reiterates | Hold | — |
| 14 Jan 2025 | Needham | Reiterates | Hold | — |
| 8 Nov 2024 | Needham | Reiterates | Hold | — |
| 7 Aug 2024 | Needham | Reiterates | Hold | — |
| 8 May 2024 | Needham | Reiterates | Hold | — |
| 8 May 2024 | Stifel | Maintains | Hold | — |
| 9 Apr 2024 | Needham | Reiterates | Hold | — |
| 15 Feb 2024 | William Blair | Upgrade | Outperform | — |
| 8 Nov 2023 | JP Morgan | Maintains | Underweight | — |
| 8 Aug 2023 | JP Morgan | Downgrade | Underweight | — |
| 8 Aug 2023 | Stifel | Maintains | Hold | — |
| 14 July 2023 | Needham | Downgrade | Hold | — |
| 20 Apr 2023 | Needham | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INGN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Inogen, Inc. returned −31.6% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 91% of US stocks
Cheaper than 84% of US stocks
Cheaper than 75% of US stocks
Cheaper than 83% of US stocks
Higher than 34% of US stocks
Higher than 40% of US stocks
Higher than 56% of US stocks
Higher than 27% of US stocks
Higher than 22% of US stocks
Higher than 34% of US stocks
Higher than 31% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Inogen, Inc. has a market value of $153.1M and an enterprise value of $63.4M.
Revenue in the twelve months to 30 June 2026: $354.3M. The latest quarter grew 3.0% year on year.
Net income over the same four quarters: −$24.6M, a −6.9% net margin.
Diluted earnings per share, trailing twelve months: $−0.90.
Free cash flow in the twelve months to 30 June 2026: −$9.7M.
Trailing P/E: −6.7×; forward P/E: −36.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Inogen, Inc. employs 753 people — $471K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Inogen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Inogen announced the divestiture of its U.S. oxygen rental business to Rotech. The announcement was made via a press release from the company's Beverly, Massachusetts location.
Why it matters — INGN watchers would care because the divestiture represents a significant change to the company's U.S. business structure and operations.
A Zacks Investment Research article discusses why investors should retain Inogen stock, citing portable oxygen concentrator (POC) demand, new products, and international growth as supporting its outlook, while noting U.S. channel shifts and distributor timing as risks.
Why it matters — A Inogen watcher would care because the article highlights the balance of growth drivers and specific risks that could shape the company's near-term performance.
Zacks Investment Research notes that Inogen's low valuation and improving margins are offset by weak U.S. sales and rental performance despite strong international demand.
Why it matters — For INGN watchers, the piece highlights the ongoing tension between the company's discounted valuation and the risks posed by its domestic sales challenges.
Inogen lowered its 2026 revenue outlook, citing ongoing pressure in the U.S. channel. The company is relying on international growth, new products, and cost control to provide support.
Why it matters — INGN watchers would care because the reduced guidance signals weaker near-term U.S. demand expectations that could weigh on the company's performance.
Inogen reported Q2 earnings that beat expectations, with total revenues up 3% year-over-year driven by a 14.8% increase in international sales, though the company cut its 2026 revenue outlook due to weakness in the U.S. market.
Why it matters — INGN investors would note the mixed signals of an earnings beat and international growth offset by a lowered 2026 outlook tied to ongoing U.S. market struggles.
The 2 Wall Street analysts covering Inogen, Inc. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Inogen, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Inogen, Inc. 81 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Inogen, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +102.0% from the last close, and Ticker Nerd's factor model ranks Inogen, Inc. 81 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Inogen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
Inogen, Inc. returned -31.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions.
The most recent item we track (Business Wire, 30 Sept 2026): "Inogen Announces Divestiture of Its U.S. Oxygen Rental Business to Rotech". Inogen announced the divestiture of its U.S. oxygen rental business to Rotech. The announcement was made via a press release from the company's Beverly, Massachusetts location.
Inogen Inc. is a medical technology company focused on respiratory care for people living with chronic respiratory conditions. The company develops, manufactures, and markets portable oxygen concentrators for homecare use, helping patients receive supplemental long-term oxygen therapy in a more mobile form than traditional oxygen systems. Its product portfolio also includes stationary home oxygen concentrators, batteries, accessories, rental offerings, and airway-clearance solutions. Inogen serves patients through direct-to-consumer, business-to-business, and international channels, working with home medical equipment providers, prescribers, and distributors to broaden access to respiratory therapy products. Headquartered in Beverly, Massachusetts, Inogen plays a specialized role in the respiratory health market by addressing everyday oxygen therapy needs across home, travel, and other ambulatory settings.
CEO Mr. Kevin R. M. Smith · 753 employees · United States · https://www.provider.inogen.com
